Clinical Outcomes of IVUS-guided Stenting Using the Boston Scientific Vici® Venous Stent System in Treating Patients With Chronic Non-malignant Iliofemoral Vein Obstruction

NCT04856592 | Withdrawn FDA Device

• 1 other identifier: S2484
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The APAC VICI Study is a prospective, non-randomized, multicenter, single-arm study. The purpose of this study is to evaluate the clinical results of using the Boston Scientifc's Vici Venous Stent (Vici stent) to treat significant blockage in the iliofemoral veins under the guidance of intravascular ultrasound (IVUS) in ethnic Chinese patient population. The study will assess the safety and effectiveness of Vici stent implanted under the guidance of the Boston Scientific's IVUS technology (by using Opticross 35 catheter) for treating adult ethnic Chinese patients with symptomatic chronic venous obstruction in the iliofemoral veins. During the trial, anticoagulant or antiplatlet therapy will be administered for 6 - 12 months post index procedure. Ongoing dynamic data safety monitoring will be performed throughout the trial to minimize subject risk. All enrolled subjects receiving the Vici stent treatment will be followed for 24 months post index procedure.

Conditions

Chronic Venous Disorder; Venous Outflow Obstruction; Systemic Vein Outflow of Iliofemoral Vein

Outcome Measures

Primary Outcomes (2)

• The primary patency rate at 12 months post index procedure

  Defined as freedom from occlusion by thrombosis AND freedom from surgical or endovascular intervention on target vessel which are found to have restenosis or stent occlusion to maintain patency AND freedom from in-stent stenosis more than 50% by DUS.

  12 month

• Major Adverse Events within 30 days post index procedure

  The composite endpoint of below major adverse events (MAE) adjudicated by the Clinical Events Committee (CEC) within 30 days post index procedure: * Device or procedure-related death * Device or procedure-related bleeding at the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention or blood transfusion ≥ 2 units * Device or procedure-related arterial or venous injury occurring in the target vessel segment and/or target lesion or at the access site requiring surgical or endovascular intervention * Device or procedure related acute DVT outside of the target vein segment * Clinically significant pulmonary embolism defined as being symptomatic with chest pain, hemoptysis, dyspnea, hypoxia etc… AND be documented on CT * Stent embolization * Stent thrombosis

  30 days

Study Arms (1)

VICI Stent

EXPERIMENTAL

Device: Boston Scientific Vici® Venous Stent System; Device: Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter)

Interventions

Boston Scientific Vici® Venous Stent System DEVICE

The Vici Venous Stent System comprises two components: the implantable endoprosthesis and its stent delivery system, a 9F over-the-wire system available in a 100cm length and compatible with 0.035in (0.89mm) guidewires

VICI Stent

Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter) DEVICE

The Opticross 35 catheter is designed for use with a guidewire measuring ≤0.035 in (0.89 mm) in diameter and an introducer sheath of 8F (2.67 mm) or larger. The working length of OC35 catheter is 105 cm.

VICI Stent

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ethnic Chinese subjects of age ≥ 18 years (or meet age requirements per local law)
• Subjects willing to provide written informed consent prior to the study and AND willing to comply with all follow-up evaluations at the specified times
• Subjects with presence of unilateral, clinically significant, chronic non-malignant obstruction of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof, defined as a \> 50% reduction in target vessel lumen diameter measured by venogram and/or IVUS during procedure
• Clinically significant venous obstruction defined as meeting at least one of the following clinical indicators:
• Clinical severity class of CEAP classification ≥ 3
• rVCSS Pain Score ≥ 2
• Negative pregnancy test in female subjects of potential child-bearing
• Intention to stent the target lesion only with the Vici Stent(s)

You may not qualify if:

• Pre-Procedural EC--
• Subjects with presence or history of clinically significant pulmonary emboli within 6 months prior to enrollment.
• Subjects with venous obstruction that extends into the inferior vena cava
• Subjects with contralateral disease of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof with planned treatment within 30 days after enrollment
• Subjects with a life expectancy \< 12 months
• Female of childbearing potential who is pregnant or plans to become pregnant during the duration of the clinical study (Note: subjects who plan to become pregnant after 12-month follow-up visit may be included in the trial at the discretion of treating physician)
• A. Subjects with uncontrolled or active coagulopathy OR
• B. Subjects with known uncorrectable bleeding diathesis with the following definitions:
• Uncorrected INR ≥ 2.0 or aPTT ≥ 1.5X normal local lab value
• Platelet count \< 80,000
• Subjects with uncorrected hemoglobin of ≤ 9 g/dL
• Subjects with an estimated glomerular filtration rate (eGFR) \< 30 mL/min. In patients with diabetes mellitus, eGFR \< 45 mL/min.
• Subjects have known hypersensitivity to nickel or titanium
• Subjects have contrast agent allergy that cannot be managed adequately with pre-medication
• Subjects will have intended concurrent thrombolysis or thrombectomy procedure OR intended or planned (within 30 days) adjuvant procedure such as creation of temporary AV fistula, placement of IVC filter, endovenectomy or saphenous vein ablation

Sponsors & Collaborators

• Boston Scientific Corporation: lead

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 12, 2021
• First Posted: April 23, 2021
• Study Start: December 31, 2021
• Primary Completion: December 31, 2022
• Study Completion: December 31, 2023
• Last Updated: November 1, 2021

Record last verified: 2021-10